Laparoscopically assisted radical vaginal hysterectomy vs. radical abdominal hysterectomy for cervical cancer: a match controlled study

被引:116
作者
Jackson, KS [1 ]
Das, N [1 ]
Naik, R [1 ]
Lopes, AD [1 ]
Godfrey, KA [1 ]
Hatem, MH [1 ]
Monaghan, JM [1 ]
机构
[1] Queen Elizabeth Hosp, No Gynaecol Oncol Ctr, Gateshead NE9 6SX, England
关键词
radical hysterectomy; laparoscopic-assisted; morbidity; complications;
D O I
10.1016/j.ygyno.2004.07.055
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Objectives. The technical feasibility of laparoscopically assisted radical vaginal hysterectomy has been well described, but its advantages over the open technique remain largely unproven. We reviewed and compared our experiences with both approaches. Methods. All patients undergoing laparoscopically assisted radical vaginal hysterectomy (LARVH) between 1996 and 2003 were identified and matched for age, FIGO stage, histological subtype and nodal metastases using a control group of women who underwent radical abdominal hysterectomy (RAH) during the same time period. Results. Fifty-seven women were listed for LARVH, resulting in five conversions. Fifty cases were matched successfully using the criteria above. The majority of cases were FIGO stage IB1. Statistically significant differences (P < 0.05) were present when the following were compared for LARVH vs. RAH: duration of surgery (median 180 vs. 120 min), blood loss (median 350 vs. 875 ml), hospital stay (median 5 days vs. 8 days) and duration of continuous bladder catheterisation (median 3 days vs. 7 days). There were no statistically significant differences with regard to nodal yield, completeness of surgical margins or perioperative complication rate. Four major complications (8%, three cystotomies and one enterotomy) occurred in the LARVH group and three in the RAH group (6%, one pulmonary embolism, one ureteric injury and one major haemorrhage). Three women in LARVH group had seen a specialist regarding postoperative bladder dysfunction, versus 12 in the RAH group (P 0.04). No patients in the LARVH group reported constipation requiring regular laxatives, versus six in the RAH group (P = 0.03). Median follow-up was 52 months for LARVH and 49 months for RAH. There was no significant difference between recurrence rates or overall survival (94% for LARVH vs. 96% for RAH). Conclusions. Despite the inherent limitations of LARVH and its associated learning curve, the procedure conveys many advantages over the open technique in terms of blood loss, transfusion requirement and hospital stay. In addition, the incidence of postoperative bladder and bowel dysfunction appears low-suggesting improved quality of life-without compromising survival. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:655 / 661
页数:7
相关论文
共 36 条
[1]
[Anonymous], CME J GYNECOLOGY ONC
[2]
[Anonymous], GYNAECOLOGICAL ENDOS
[3]
[Anonymous], 2002, CLIN GYNECOLOGIC ONC
[4]
RADICAL HYSTERECTOMY - A RANDOMIZED STUDY COMPARING 2 TECHNIQUES FOR RESECTION OF THE CARDINAL LIGAMENT [J].
BENEDETTIPANICI, P ;
SCAMBIA, G ;
BAIOCCHI, G ;
MANESCHI, F ;
GREGGI, S ;
MANCUSO, S .
GYNECOLOGIC ONCOLOGY, 1993, 50 (02) :226-231
[5]
Lymphatic spread of cervical cancer: An anatomical and pathological study based on 225 radical hysterectomies with systematic pelvic and aortic lymphadenectomy [J].
BenedettiPanici, P ;
Maneschi, F ;
Scambia, G ;
Greggi, S ;
Cutillo, G ;
DAndrea, G ;
Rabitti, C ;
Coronetta, F ;
Capelli, A ;
Mancuso, S .
GYNECOLOGIC ONCOLOGY, 1996, 62 (01) :19-24
[6]
Patient-rating of distressful symptoms after treatment for early cervical cancer [J].
Bergmark, K ;
Åvall-Lundqvist, E ;
Dickman, PW ;
Henningsohn, L ;
Steineck, G .
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2002, 81 (05) :443-450
[7]
Butler-Manuel S. A., 1999, Journal of Obstetrics and Gynaecology (Abingdon), V19, P180
[8]
VAGINALLY ASSISTED LAPAROSCOPIC RADICAL HYSTERECTOMY [J].
CANIS, M ;
MAGE, G ;
WATTIEZ, A ;
POULY, JL ;
CHAPRON, C ;
BRUHAT, MA .
JOURNAL OF GYNECOLOGIC SURGERY, 1992, 8 (02) :103-105
[9]
CHILDERS JM, 1995, CURR OPIN OBSTET GYN, V7, P57
[10]
Comerci G, 1998, INT J GYNECOL CANCER, V8, P23